Mirum Pharmaceuticals/$MIRM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Ticker
$MIRM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
334
ISIN
US6047491013
Website
MIRM Metrics
BasicAdvanced
$2.5B
-
-$1.61
0.96
-
Price and volume
Market cap
$2.5B
Beta
0.96
52-week high
$54.23
52-week low
$28.56
Average daily volume
424K
Financial strength
Current ratio
3.22
Quick ratio
2.928
Long term debt to equity
135.264
Total debt to equity
135.969
Interest coverage (TTM)
-5.33%
Profitability
EBITDA (TTM)
-52.304
Gross margin (TTM)
77.10%
Net profit margin (TTM)
-20.39%
Operating margin (TTM)
-20.12%
Effective tax rate (TTM)
-1.89%
Revenue per employee (TTM)
$1,140,000
Management effectiveness
Return on assets (TTM)
-7.11%
Return on equity (TTM)
-33.06%
Valuation
Price to revenue (TTM)
6.431
Price to book
10.77
Price to tangible book (TTM)
-237.24
Price to free cash flow (TTM)
-87.519
Free cash flow yield (TTM)
-1.14%
Free cash flow per share (TTM)
-58.04%
Growth
Revenue change (TTM)
69.31%
Earnings per share change (TTM)
-56.17%
3-year revenue growth (CAGR)
127.92%
3-year earnings per share growth (CAGR)
-11.04%
What the Analysts think about MIRM
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
Bulls say / Bears say
Mirum Pharmaceuticals received FDA approval for CTEXLI™ (chenodiol) Tablets for the treatment of Cerebrotendinous Xanthomatosis (CTX), marking a significant expansion of their product portfolio. (businesswire.com)
The company reported 2024 net product sales of $336.4 million, exceeding the upper end of their guidance range, indicating strong market performance. (businesswire.com)
Analysts have maintained a 'Buy' rating on Mirum Pharmaceuticals, with an average price target of $53.00, suggesting potential upside from current levels. (markets.businessinsider.com)
Leerink Partners issued a negative outlook for Mirum Pharmaceuticals' earnings, raising concerns about future profitability. (reporter.am)
Insider selling activity, including CEO Christopher Peetz selling 6,837 shares, may signal potential concerns about the company's future prospects. (tickerreport.com)
The company's forecasted breakeven date has been pushed back to 2026, indicating prolonged periods of unprofitability. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MIRM Financial Performance
Revenues and expenses
MIRM Earnings Performance
Company profitability
MIRM News
AllArticlesVideos
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 week ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mirum Pharmaceuticals stock?
Mirum Pharmaceuticals (MIRM) has a market cap of $2.5B as of June 20, 2025.
What is the P/E ratio for Mirum Pharmaceuticals stock?
The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of June 20, 2025.
Does Mirum Pharmaceuticals stock pay dividends?
No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Mirum Pharmaceuticals dividend payment date?
Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.
What is the beta indicator for Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.